Collaboration
The Max Planck Institute of Biochemistry spin-out Kinaxo Biotechnologies GmbH has announced that it has entered into a second collaboration with Roche Diagnostics GmbH in Penzberg, Germany, under which Kinaxo will apply its phosphoproteomics technology PhosphoScout to support targeted treatment approaches currently under development at Roche. Financial details of the agreement were not disclosed.
PhosphoScout makes it possible to monitor protein phosphorylation happening in response to antibody or kinase inhibitor treatment. Up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture.
The technology will be applied for analysing the mode of action and for stratifying patient populations in trials of targeted therapies.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.